Key Drivers
- Strong Liquidity
- Thin Margins
- High Cash Flow
AIAI Summary
PCRX is now best viewed as a cash-generative, execution-sensitive turnaround story rather than a simple EXPAREL growth play, where upside depends on converting strong gross margins and steady FCF into real operating leverage while the activist/proxy overhang and softer guidance keep the stock range-bound until management proves sustainable profitability.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Thin Margins
- •High Cash Flow
PCRX is financially stable and cash-generative, but thin margins and a rich earnings multiple limit upside despite solid liquidity.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Tightening range
- •Near support
PCRX has slipped about 8% over the last month into a short-term downtrend marked by lower highs, though it is near support at $22.64 and could bounce if that level holds.
Rebounds have repeatedly stalled below prior highs as the decline slowed into a tighter $22.64 to $23.53 band
Sentiment & News
Key News Insights:
- •Earnings Miss
- •Proxy Battle
- •Acquisition Growth
Pacira's Q1 revenue grew 5% with EXPAREL volume up and ZILRETTA on track, but an earnings miss and escalating proxy fight overshadowed the product progress, while PharmaCorp RX continued expanding via acquisitions.
PCRX is likely to stay volatile as Pacira's mixed results and board contest weigh on sentiment, even as product and expansion news provide some offset
Similar Companies in Healthcare
Other companies in the same sector with AI ratings